| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 7.56▼ | 7.57▼ | 7.55▼ | 7.04▲ | 6.50▲ |
| MA10 | 7.62▼ | 7.58▼ | 7.66▼ | 6.86▲ | 5.42▲ |
| MA20 | 7.65▼ | 7.73▼ | 7.84▼ | 6.59▲ | 4.71▲ |
| MA50 | 7.61▼ | 7.39▼ | 7.03▲ | 5.29▲ | 3.08▲ |
| MA100 | 7.77▼ | 7.01▲ | 6.71▲ | 4.64▲ | 2.78▲ |
| MA200 | 7.78▼ | 6.70▲ | 6.00▲ | 3.32▲ | 4.04▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.029▼ | -0.061▼ | -0.104▼ | 0.054▲ | 0.234▲ |
| RSI | 22.786▼ | 36.791▼ | 47.003▼ | 62.339▲ | 74.894▲ |
| STOCH | 3.907▼ | 51.174 | 17.858▼ | 67.533 | 84.131▲ |
| WILL %R | -98.810▼ | -99.231▼ | -99.600▼ | -35.170 | -24.634▲ |
| CCI | -350.000▼ | -146.942▼ | -99.483 | 109.844▲ | 155.661▲ |
|
Wednesday, March 04, 2026 04:20 AM
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with ...
|
|
Wednesday, February 04, 2026 07:19 AM
The following slide deck was published by Minerva Neurosciences, Inc. in conjunction with this event.
|
|
Saturday, December 06, 2025 10:52 AM
The average one-year price target for Minerva Neurosciences (NasdaqCM:NERV) has been revised to $4.59 / share. This is an increase of 12.50% from the prior estimate of $4.08 dated November 14, 2025.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/03/26 | 7.81 | 7.81 | 7.285 | 7.315 | 209,077 |
| 10/03/26 | 7.69 | 8.56 | 7.5901 | 7.94 | 354,446 |
| 09/03/26 | 6.02 | 8.15 | 6.00 | 8.00 | 586,595 |
| 06/03/26 | 5.85 | 6.37 | 5.805 | 6.01 | 86,658 |
| 05/03/26 | 6.64 | 6.70 | 5.0201 | 5.94 | 594,403 |
| 04/03/26 | 6.79 | 7.09 | 6.7101 | 6.83 | 105,480 |
| 03/03/26 | 6.80 | 7.17 | 6.80 | 6.86 | 143,714 |
| 02/03/26 | 6.42 | 6.92 | 6.23 | 6.90 | 206,348 |
| 27/02/26 | 6.15 | 6.67 | 6.15 | 6.60 | 82,745 |
| 26/02/26 | 6.23 | 6.34 | 6.112 | 6.23 | 30,300 |
|
|
||||
|
|
||||
|
|